Evidence map›Paper›PMID 42155035›Full record

ArticleBioconjugate chemistry2026

A Theranostic Study of

Huayan Zhang, Mingming Tang, Xiaofei Hao, Binwei Lin, Huan Du, Hu Long, Jiangjiang Hu, Rui Luo, Wei Wu, Xiaobo Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huayan ZhangCollege of Life Sciences and Agri-forestry, Southwest University of Science and Technology, Mianyang 621000, China.
Mingming TangClinical Medical School, North Sichuan Medical College, Nanchong 637000, China.
Xiaofei HaoMianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China.
Binwei LinNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China.
Huan DuMianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China.
Hu LongSichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu 611138, China.
Jiangjiang HuSichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu 611138, China.
Rui LuoDepartment of Nuclear Medicine, Central Hosital of Mianyang, Mianyang 621000, China.
Wei WuSchool of National Defense Science and Technology, Southwest University of Science and Technology, Mianyang 621000, China.
Xiaobo DuCollege of Life Sciences and Agri-forestry, Southwest University of Science and Technology, Mianyang 621000, China.ORCID 0000-0001-6348-0636

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is highly aggressive with limited diagnostic and therapeutic options. ADAM9 is overexpressed in TNBC and may serve as a theranostic target. Therefore, this study aims to develop [

Indexed as

ADAM ProteinsImmunoconjugatesLutetiumMembrane ProteinsRadioisotopesTheranostic NanomedicineTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceMice, NudeTissue DistributionADAM9 protein, humanADAM ProteinsImmunoconjugatesLutetiumLutetium-177Membrane ProteinsRadioisotopes

Identifiers

PMID42155035
PMCPMC13281384

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.